8-K: Twist Bioscience Reports Record Q3 Revenue, Profit

Twist Bioscience announced record third-quarter fiscal 2025 revenue of $96.1 million and achieved net income of $20.4 million, significantly improving profitability and raising full-year guidance.

Summary

• Total revenues for the third quarter of fiscal 2025 reached a record $96.1 million, an 18% increase compared to $81.5 million in the same period of fiscal 2024, marking the 10th consecutive quarter of sequential growth.
• Gross margin significantly improved to 53.4% in Q3 FY25, up from 43.3% in Q3 FY24, an increase of 10.1 percentage points.
• The company reported a net income attributable to common stockholders of $20.4 million, or $0.34 per share, for Q3 FY25, a substantial improvement from a net loss of $85.6 million, or $1.47 per share, in Q3 FY24.
• Adjusted EBITDA for Q3 FY25 was $(8.0) million, a considerable improvement from $(22.0) million in Q3 FY24.
• Twist Bioscience shipped products to approximately 2,484 customers and approximately 237,000 genes in Q3 FY25, up from 2,300 customers and 212,000 genes in Q3 FY24.
• Full-year fiscal 2025 revenue guidance was updated to a range of $374.0 million to $376.0 million, indicating 19% to 20% year-over-year growth.
• Full-year fiscal 2025 gross margin guidance was raised to 50.5% to 51.0% from the previous 49.5%.
• Full-year fiscal 2025 adjusted EBITDA guidance improved to approximately $(45.0) million to $(47.0) million from the previous $(48.0) million to $(53.0) million.
• The company expects to achieve adjusted EBITDA breakeven by the end of fiscal 2026.

Sentiment

Score: 9

Explanation: The filing indicates strong positive momentum with record revenue, significant gross margin expansion, a shift to net income, and improved adjusted EBITDA. The raised full-year guidance and clear path to EBITDA breakeven by fiscal 2026 further reinforce a highly positive outlook, suggesting robust operational execution and strategic progress.

Positives

• Achieved record revenue of $96.1 million in Q3 FY25, representing an 18% increase year-over-year and the 10th consecutive quarter of sequential growth.
• Significant improvement in gross margin to 53.4% in Q3 FY25, up 10.1 percentage points from 43.3% in Q3 FY24.
• Transitioned from a net loss of $85.6 million in Q3 FY24 to a net income of $20.4 million in Q3 FY25.
• Reduced adjusted EBITDA loss to $(8.0) million in Q3 FY25 from $(22.0) million in Q3 FY24.
• Increased customer base to 2,484 and genes shipped to 237,000 in Q3 FY25.
• Raised full-year fiscal 2025 gross margin guidance to 50.5%-51.0% and improved adjusted EBITDA guidance to $(45.0)M-$(47.0)M.
• Expanded collaborations with Ginkgo Bioworks and Element Biosciences, enhancing product offerings and market reach.
• Launched new products and services, including expanded Express turnaround time for Gene Fragments and a humanized transgenic mouse model for antibody discovery.

Negatives

• Selling, general and administrative expenses increased to $63.4 million in Q3 FY25 from $56.8 million in Q3 FY24, partly due to a $2.8 million increase in non-cash stock-based compensation.
• Despite significant improvement, the company still reported a negative adjusted EBITDA of $(8.0) million for the quarter.

Risks

• Ability to attract new customers and retain and grow sales from existing customers.
• Ability to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period.
• Ability to obtain financing when necessary.
• Risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make products obsolete or non-competitive.
• Ability to expand DNA synthesis manufacturing capacity.
• Dependence on one supplier for a critical component.
• Dependence on key personnel.
• Additional regulations that could increase costs and delay commercialization efforts.
• Changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions.
• Risks associated with the spin out of Atlas Data Storage.
• Ability to maintain and enforce intellectual property protection.

Future Outlook

Twist Bioscience expects total revenue for the full fiscal year 2025 to be in the range of $374.0 million to $376.0 million, representing 19% to 20% year-over-year growth. Gross margin for fiscal 2025 is projected to be 50.5% to 51.0%, with adjusted EBITDA expected to be between $(45.0) million and $(47.0) million. The company anticipates achieving adjusted EBITDA breakeven by the end of fiscal 2026.

Management Comments

• "In the third quarter of fiscal 2025, we delivered another quarter of record revenue by focusing on delivering an exceptional customer experience, expanding our product portfolio, and deepening our reach into the long tail of the academic market across both synthetic biology and NGS."
• "We added hundreds of net new customers and launched the first in a series of planned SynBio portfolio expansions, laying the groundwork for robust, sustained growth ahead."

Industry Context

Twist Bioscience operates in the rapidly evolving synthetic biology, next-generation sequencing (NGS), and biopharma industries. The company's strong revenue growth, particularly in NGS, and significant gross margin expansion suggest effective execution in a competitive landscape. The focus on expanding product portfolios and customer reach, especially in the academic market, aligns with broader industry trends of increasing adoption of synthetic DNA tools for research and development across various applications, from medicine to agriculture. The improved profitability and path to EBITDA breakeven indicate a maturing business model in a sector often characterized by high R&D costs and initial losses.

Comparison to Industry Standards

• The 18% year-over-year revenue growth and 10th consecutive quarter of sequential growth demonstrate strong performance relative to many peers in the life sciences tools sector, which can experience more volatile demand cycles.
• The gross margin improvement from 43.3% to 53.4% is a significant operational achievement, indicating enhanced manufacturing efficiency and/or favorable product mix, which positions Twist more competitively against established players in the DNA synthesis and sequencing markets.
• The shift from a substantial net loss to a net income of $20.4 million is a critical milestone, suggesting a stronger financial footing compared to many early-stage or high-growth biotech companies that often remain unprofitable for longer periods.
• The expansion of collaborations with companies like Ginkgo Bioworks and Element Biosciences indicates a strategic alignment with key industry partners, leveraging their platforms (e.g., Element's AVITI systems) to broaden market penetration and workflow integration, a common strategy for technology providers in this space.

Stakeholder Impact

• **Shareholders**: Positive impact due to record revenue, significant gross margin improvement, and a shift to net income, indicating improved financial health and potential for future profitability. The raised guidance and path to EBITDA breakeven could lead to increased investor confidence and share price appreciation.
• **Employees**: Positive impact due to strong company performance and growth, potentially leading to job security, opportunities for advancement, and continued investment in R&D and product development.
• **Customers**: Positive impact through expanded product portfolio, improved turnaround times (e.g., Express turnaround for Gene Fragments), and enhanced collaboration offerings, leading to better service and more comprehensive solutions.
• **Suppliers**: Potential positive impact due to increased demand for components and services as the company scales its operations and expands manufacturing capacity.
• **Creditors**: Positive impact due to improved financial stability, reduced losses, and a clear path to profitability, enhancing the company's creditworthiness.

Next Steps

• Hold a conference call and live audio webcast on August 4, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update.
• Continue expanding the SynBio product portfolio as part of a planned series of expansions.
• Work towards achieving adjusted EBITDA breakeven by the end of fiscal 2026.

Key Dates

Recommendation

The filing presents exceptionally strong financial results, including record revenue, a significant improvement in gross margin, and a pivotal shift from a substantial net loss to a net income. The company also raised its full-year gross margin and adjusted EBITDA guidance, demonstrating confidence in continued operational improvements. The clear stated goal of achieving adjusted EBITDA breakeven by the end of fiscal 2026 provides a tangible target for future profitability. These factors, combined with continued customer and gene shipment growth and strategic collaborations, indicate robust business momentum and a positive trajectory for a growth equity, making it a compelling 'strong buy' for seasoned investors.

Keywords

Synthetic Biology, NGS, Next-Generation Sequencing, Biopharma, DNA Synthesis, Genomics, Biotechnology, Life Sciences, TWST, Financial Results